Litcius/Paper detail

Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States

Rahul Mudumba, Hui-Hsuan Chan, Yuanyuan Cheng, Chien-Chen Wang, Luís Correia, Jeromie Ballreich, Joseph Levy

2023Value in Health18 citationsDOIOpen Access PDF

Topics & Concepts

Trastuzumab emtansineTrastuzumabHuman Epidermal Growth Factor Receptor 2Metastatic breast cancerOncologyMedicineInternal medicineBreast cancerCancer researchCancerHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesEconomic and Financial Impacts of Cancer
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States | Litcius